<title>Bristol-Myers Squibb Co. (BMY) News & Commentary

AOL.com
About Us
Follow Us :

DJIA	15,318.23	138.38	0.91%
NASDAQ	3,482.18	30.05	0.87%
S&P 500	1,651.81	12.77	0.78%

Recent Quotes Watchlist Portfolios

market minute promo

+ Add to Portfolio

Company Photos

(Click to zoom)

Working at Bristol-Myers Squibb Co.

Priority Review for Gilead Drug - Analyst Blog

6/10/2013 by Zacks

Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High?

6/10/2013 by Seeking Alpha

Why You Should Care About This Diabetes Drug Saga

Are changes to Glaxo's Avandia a sign that the FDA is lightening up?

6/8/2013 by DailyFinance

Top-Performing Dividend Payers in Health Care with the Most Upside Potential (AET, ENSG, QCOR)

6/8/2013 by Benzinga

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

6/7/2013 by Benzinga

‘Evergreening’ Patent-Expired Drugs: Pharma Tactic

6/6/2013 by YCharts

UPDATE: Immunotherapy Cancer Drug Race Speeds Up After Medical Meeting

6/6/2013 by Smart Money

Priority Review for AZN/BMY Drug - Analyst Blog

6/6/2013 by Zacks

Immunotherapy Cancer Drug Race Speeds Up After Medical Meeting

6/6/2013 by Smart Money

Old-School Pharma/Biotech Dividend Paying Comparison

6/6/2013 by Seeking Alpha

See More Articles...